[8-K] Cardlytics, Inc. Reports Material Event
Avidity Biosciences, Inc. (RNA) 鈥� Form 144 filing
An unnamed filer has notified the SEC of an intent to sell up to 95,054 common shares through UBS Financial Services on Nasdaq around 08 Aug 2025. At the filing鈥檚 stated market price the block is worth about $4.28 million and equals roughly 0.08 % of the 120.54 million shares outstanding.
The shares derive from two sources: 29,500 shares obtained via a same-day stock-option exercise and 65,554 long-held shares first acquired in November 2012. The filer reports no sales in the prior three months and signs the standard Rule 144 representation that no non-public adverse information is known.
The notice is procedural; it neither changes RNA鈥檚 fundamentals nor includes financial results. Nevertheless, it signals a modest insider liquidity event that investors may monitor for sentiment cues.
Avidity Biosciences, Inc. (RNA) 鈥� Comunicazione Form 144
Un soggetto non identificato ha informato la SEC dell鈥檌ntenzione di vendere fino a 95.054 azioni ordinarie tramite UBS Financial Services sul Nasdaq intorno al 08 agosto 2025. Al prezzo di mercato indicato nella comunicazione, il blocco azionario vale circa 4,28 milioni di dollari e rappresenta circa lo 0,08% delle 120,54 milioni di azioni in circolazione.
Le azioni provengono da due fonti: 29.500 azioni ottenute mediante esercizio di opzioni azionarie nello stesso giorno e 65.554 azioni detenute da lungo tempo, acquisite per la prima volta nel novembre 2012. Il dichiarante segnala nessuna vendita nei tre mesi precedenti e sottoscrive la dichiarazione standard della Regola 144, affermando di non essere a conoscenza di informazioni negative non pubbliche.
La comunicazione 猫 di natura procedurale; non modifica i fondamentali di RNA n茅 include risultati finanziari. Tuttavia, indica un modesto evento di liquidit脿 interna che gli investitori potrebbero osservare come indicatore di sentiment.
Avidity Biosciences, Inc. (RNA) 鈥� Presentaci贸n Formulario 144
Un remitente an贸nimo ha notificado a la SEC su intenci贸n de vender hasta 95,054 acciones ordinarias a trav茅s de UBS Financial Services en Nasdaq alrededor del 08 de agosto de 2025. Al precio de mercado indicado en la presentaci贸n, el bloque tiene un valor aproximado de 4.28 millones de d贸lares y equivale a cerca del 0.08% de las 120.54 millones de acciones en circulaci贸n.
Las acciones provienen de dos fuentes: 29,500 acciones obtenidas mediante el ejercicio de opciones sobre acciones el mismo d铆a y 65,554 acciones mantenidas por largo tiempo, adquiridas inicialmente en noviembre de 2012. El remitente informa no haber realizado ventas en los tres meses previos y firma la declaraci贸n est谩ndar de la Regla 144, afirmando no tener conocimiento de informaci贸n adversa no p煤blica.
El aviso es de car谩cter procedimental; no altera los fundamentos de RNA ni incluye resultados financieros. No obstante, se帽ala un modesto evento de liquidez interna que los inversionistas podr铆an seguir para captar se帽ales de sentimiento.
Avidity Biosciences, Inc. (RNA) 鈥� Form 144 鞝滌稖
鞚惦獏鞚� 鞝滌稖鞛愱皜 2025雲� 8鞗� 8鞚缄步 UBS Financial Services毳� 韱淀暣 雮橃姢雼レ棎靹� 95,054欤� 氤错喌欤�毳� 毵る弰頃� 鞚橃偓毳� SEC鞐� 韱奠頄堨姷雼堧嫟. 鞝滌稖靹滌棎 氇呾嫓霅� 鞁滉皜 旮办鞙茧 鞚� 欤检嫕 敫旊鞚� 臧�旃橂姅 鞎� 428毵� 雼煬鞚措┌, 鞝勳泊 氚滍枆 欤检嫕 1鞏� 2,054毵� 欤检潣 鞎� 0.08%鞐� 頃措嫻頃╇媹雼�.
欤检嫕 於滌矘電� 霊� 臧�歆�搿�, 29,500欤�電� 雼轨澕 欤检嫕 鞓奠厴 頄夓偓搿� 旆摑頄堨溂氅�, 65,554欤�電� 2012雲� 11鞗� 觳橃潓 旆摑頃� 鞛リ赴 氤挫湢 欤检嫕鞛呺媹雼�. 鞝滌稖鞛愲姅 斓滉芳 3臧滌洈臧� 毵る弰 雮挫棴鞚� 鞐嗢潓鞚� 氤搓碃頃橂┌, 牍勱车臧� 攵�鞝曥爜 鞝曤炒臧� 鞐嗢潓鞚� 響滌 Rule 144 歆勳垹靹滌棎 靹滊獏頄堨姷雼堧嫟.
鞚措矆 韱奠電� 鞝堨皑靸侅潣 鞁犼碃搿� RNA鞚� 旮半掣 靷暛鞚措倶 鞛 瓴瓣臣鞐愲姅 氤�霃欖澊 鞐嗢姷雼堧嫟. 攴鸽煬雮� 韴瀽鞛愲摛鞚� 鞁Μ鞝� 鞁犿樃搿� 欤茧頃� 靾� 鞛堧姅 靻岅窚氇� 雮措秬鞛� 鞙犽彊靹� 鞚措菠韸胳瀯鞚� 雮橅儉雰呺媹雼�.
Avidity Biosciences, Inc. (RNA) 鈥� D茅p么t du formulaire 144
Un d茅posant anonyme a inform茅 la SEC de son intention de vendre jusqu鈥櫭� 95 054 actions ordinaires via UBS Financial Services sur le Nasdaq aux alentours du 8 ao没t 2025. Au prix de march茅 indiqu茅 dans le d茅p么t, ce bloc vaut environ 4,28 millions de dollars et repr茅sente environ 0,08 % des 120,54 millions d鈥檃ctions en circulation.
Les actions proviennent de deux sources : 29 500 actions obtenues par l鈥檈xercice d鈥檕ptions sur actions le m锚me jour et 65 554 actions d茅tenues de longue date, acquises initialement en novembre 2012. Le d茅posant d茅clare aucune vente au cours des trois derniers mois et signe la d茅claration standard de la R猫gle 144 affirmant qu鈥檃ucune information d茅favorable non publique n鈥檈st connue.
L鈥檃vis est purement proc茅dural ; il ne modifie pas les fondamentaux de RNA ni ne comprend de r茅sultats financiers. N茅anmoins, il signale un 茅v茅nement modeste de liquidit茅 interne que les investisseurs pourraient suivre comme un indicateur de sentiment.
Avidity Biosciences, Inc. (RNA) 鈥� Form 144 Meldung
Ein nicht namentlich genannter Einreicher hat der SEC die Absicht mitgeteilt, bis zu 95.054 Stammaktien 眉ber UBS Financial Services an der Nasdaq etwa am 08. August 2025 zu verkaufen. Zum angegebenen Marktpreis ist das Aktienpaket etwa 4,28 Millionen US-Dollar wert und entspricht ungef盲hr 0,08 % der 120,54 Millionen ausstehenden Aktien.
Die Aktien stammen aus zwei Quellen: 29.500 Aktien wurden durch Aus眉bung von Aktienoptionen am selben Tag erworben und 65.554 lang gehaltene Aktien, die erstmals im November 2012 erworben wurden. Der Einreicher meldet keine Verk盲ufe in den letzten drei Monaten und unterzeichnet die Standarderkl盲rung gem盲脽 Regel 144, dass keine nicht 枚ffentlichen negativen Informationen bekannt sind.
Die Mitteilung ist rein formell; sie 盲ndert weder die Fundamentaldaten von RNA noch enth盲lt sie Finanzzahlen. Dennoch signalisiert sie ein kleines Insider-Liquidit盲tsereignis, das Investoren als Stimmungsindikator beobachten k枚nnten.
- None.
- Insider liquidity event: proposed sale of 95,054 shares valued at $4.28 M could be viewed as a mild bearish sentiment signal, though size is immaterial to float.
Insights
TL;DR: Small insider sale (0.08 % float) 鈥� informational, not fundamentally damaging.
At just 95 k shares, the planned disposal equates to 0.08 % of outstanding stock and under 2 days of average volume, limiting market impact. The split between newly exercised options and decade-old holdings suggests routine diversification rather than strategic exit. Absence of past-quarter sales and the Rule 144 attestation reduce concern over undisclosed negatives. Overall signal is neutral; worth noting but unlikely to affect valuation unless followed by larger sequential sales.
Avidity Biosciences, Inc. (RNA) 鈥� Comunicazione Form 144
Un soggetto non identificato ha informato la SEC dell鈥檌ntenzione di vendere fino a 95.054 azioni ordinarie tramite UBS Financial Services sul Nasdaq intorno al 08 agosto 2025. Al prezzo di mercato indicato nella comunicazione, il blocco azionario vale circa 4,28 milioni di dollari e rappresenta circa lo 0,08% delle 120,54 milioni di azioni in circolazione.
Le azioni provengono da due fonti: 29.500 azioni ottenute mediante esercizio di opzioni azionarie nello stesso giorno e 65.554 azioni detenute da lungo tempo, acquisite per la prima volta nel novembre 2012. Il dichiarante segnala nessuna vendita nei tre mesi precedenti e sottoscrive la dichiarazione standard della Regola 144, affermando di non essere a conoscenza di informazioni negative non pubbliche.
La comunicazione 猫 di natura procedurale; non modifica i fondamentali di RNA n茅 include risultati finanziari. Tuttavia, indica un modesto evento di liquidit脿 interna che gli investitori potrebbero osservare come indicatore di sentiment.
Avidity Biosciences, Inc. (RNA) 鈥� Presentaci贸n Formulario 144
Un remitente an贸nimo ha notificado a la SEC su intenci贸n de vender hasta 95,054 acciones ordinarias a trav茅s de UBS Financial Services en Nasdaq alrededor del 08 de agosto de 2025. Al precio de mercado indicado en la presentaci贸n, el bloque tiene un valor aproximado de 4.28 millones de d贸lares y equivale a cerca del 0.08% de las 120.54 millones de acciones en circulaci贸n.
Las acciones provienen de dos fuentes: 29,500 acciones obtenidas mediante el ejercicio de opciones sobre acciones el mismo d铆a y 65,554 acciones mantenidas por largo tiempo, adquiridas inicialmente en noviembre de 2012. El remitente informa no haber realizado ventas en los tres meses previos y firma la declaraci贸n est谩ndar de la Regla 144, afirmando no tener conocimiento de informaci贸n adversa no p煤blica.
El aviso es de car谩cter procedimental; no altera los fundamentos de RNA ni incluye resultados financieros. No obstante, se帽ala un modesto evento de liquidez interna que los inversionistas podr铆an seguir para captar se帽ales de sentimiento.
Avidity Biosciences, Inc. (RNA) 鈥� Form 144 鞝滌稖
鞚惦獏鞚� 鞝滌稖鞛愱皜 2025雲� 8鞗� 8鞚缄步 UBS Financial Services毳� 韱淀暣 雮橃姢雼レ棎靹� 95,054欤� 氤错喌欤�毳� 毵る弰頃� 鞚橃偓毳� SEC鞐� 韱奠頄堨姷雼堧嫟. 鞝滌稖靹滌棎 氇呾嫓霅� 鞁滉皜 旮办鞙茧 鞚� 欤检嫕 敫旊鞚� 臧�旃橂姅 鞎� 428毵� 雼煬鞚措┌, 鞝勳泊 氚滍枆 欤检嫕 1鞏� 2,054毵� 欤检潣 鞎� 0.08%鞐� 頃措嫻頃╇媹雼�.
欤检嫕 於滌矘電� 霊� 臧�歆�搿�, 29,500欤�電� 雼轨澕 欤检嫕 鞓奠厴 頄夓偓搿� 旆摑頄堨溂氅�, 65,554欤�電� 2012雲� 11鞗� 觳橃潓 旆摑頃� 鞛リ赴 氤挫湢 欤检嫕鞛呺媹雼�. 鞝滌稖鞛愲姅 斓滉芳 3臧滌洈臧� 毵る弰 雮挫棴鞚� 鞐嗢潓鞚� 氤搓碃頃橂┌, 牍勱车臧� 攵�鞝曥爜 鞝曤炒臧� 鞐嗢潓鞚� 響滌 Rule 144 歆勳垹靹滌棎 靹滊獏頄堨姷雼堧嫟.
鞚措矆 韱奠電� 鞝堨皑靸侅潣 鞁犼碃搿� RNA鞚� 旮半掣 靷暛鞚措倶 鞛 瓴瓣臣鞐愲姅 氤�霃欖澊 鞐嗢姷雼堧嫟. 攴鸽煬雮� 韴瀽鞛愲摛鞚� 鞁Μ鞝� 鞁犿樃搿� 欤茧頃� 靾� 鞛堧姅 靻岅窚氇� 雮措秬鞛� 鞙犽彊靹� 鞚措菠韸胳瀯鞚� 雮橅儉雰呺媹雼�.
Avidity Biosciences, Inc. (RNA) 鈥� D茅p么t du formulaire 144
Un d茅posant anonyme a inform茅 la SEC de son intention de vendre jusqu鈥櫭� 95 054 actions ordinaires via UBS Financial Services sur le Nasdaq aux alentours du 8 ao没t 2025. Au prix de march茅 indiqu茅 dans le d茅p么t, ce bloc vaut environ 4,28 millions de dollars et repr茅sente environ 0,08 % des 120,54 millions d鈥檃ctions en circulation.
Les actions proviennent de deux sources : 29 500 actions obtenues par l鈥檈xercice d鈥檕ptions sur actions le m锚me jour et 65 554 actions d茅tenues de longue date, acquises initialement en novembre 2012. Le d茅posant d茅clare aucune vente au cours des trois derniers mois et signe la d茅claration standard de la R猫gle 144 affirmant qu鈥檃ucune information d茅favorable non publique n鈥檈st connue.
L鈥檃vis est purement proc茅dural ; il ne modifie pas les fondamentaux de RNA ni ne comprend de r茅sultats financiers. N茅anmoins, il signale un 茅v茅nement modeste de liquidit茅 interne que les investisseurs pourraient suivre comme un indicateur de sentiment.
Avidity Biosciences, Inc. (RNA) 鈥� Form 144 Meldung
Ein nicht namentlich genannter Einreicher hat der SEC die Absicht mitgeteilt, bis zu 95.054 Stammaktien 眉ber UBS Financial Services an der Nasdaq etwa am 08. August 2025 zu verkaufen. Zum angegebenen Marktpreis ist das Aktienpaket etwa 4,28 Millionen US-Dollar wert und entspricht ungef盲hr 0,08 % der 120,54 Millionen ausstehenden Aktien.
Die Aktien stammen aus zwei Quellen: 29.500 Aktien wurden durch Aus眉bung von Aktienoptionen am selben Tag erworben und 65.554 lang gehaltene Aktien, die erstmals im November 2012 erworben wurden. Der Einreicher meldet keine Verk盲ufe in den letzten drei Monaten und unterzeichnet die Standarderkl盲rung gem盲脽 Regel 144, dass keine nicht 枚ffentlichen negativen Informationen bekannt sind.
Die Mitteilung ist rein formell; sie 盲ndert weder die Fundamentaldaten von RNA noch enth盲lt sie Finanzzahlen. Dennoch signalisiert sie ein kleines Insider-Liquidit盲tsereignis, das Investoren als Stimmungsindikator beobachten k枚nnten.
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||||||||
| (Address of principal executive offices, including zip code) | |||||||||||
| (Registrant's telephone, including area code) | |||||||||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Title of each class | Trading symbol | Name of each exchange on which registered | ||||||
| Emerging growth company | |||||
| Exhibit | Exhibit Description | |||||||
| 99.1 | Press release dated August 6, 2025 | |||||||
| 104 | The cover page from Cardlytics, Inc.’s Form 8-K filed on August 6, 2025, formatted in Inline XBRL. | |||||||
| Cardlytics, Inc. | |||||||||||
| Date: | August 6, 2025 | By: | /s/ Alexis DeSieno | ||||||||
| Alexis DeSieno | |||||||||||
Chief Financial Officer (Principal Financial and Accounting Officer) | |||||||||||
Source:
FAQ
How many Avidity Biosciences (RNA) shares are being sold under this Form 144?
What is the approximate market value of the shares in the RNA Form 144 filing?
When is the planned sale date for the RNA shares?
What percentage of Avidity Biosciences鈥� outstanding shares does the sale represent?
Were any shares sold by the filer in the prior three months?
